Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Immunohistochemical Study to Evaluate the Prognostic Significance of Four Biomolecular Markers in Radiotherapy of Nasopharyngeal Carcinoma

방사선 치료를 받은 코인두암의 생체분자적 예후 인자를 찾기 위한 면역조직화학염색 연구

  • Kim, Yeon-Joo (Department of Radiation Oncology, Seoul National University College of Medicine) ;
  • Lee, Seung-Hee (Department of Radiation Oncology, Seoul National University College of Medicine) ;
  • Wu, Hong-Gyun (Department of Radiation Oncology, Seoul National University College of Medicine) ;
  • Go, Heoun-Jeong (Department of Pathology, Seoul National University College of Medicine) ;
  • Jeon, Yoon-Kyung (Department of Pathology, Seoul National University College of Medicine)
  • 김연주 (서울대학교 의과대학 방사선종양학교실) ;
  • 이승희 (서울대학교 의과대학 방사선종양학교실) ;
  • 우홍균 (서울대학교 의과대학 방사선종양학교실) ;
  • 고현정 (서울대학교 의과대학 병리학교실) ;
  • 전윤경 (서울대학교 의과대학 병리학교실)
  • Received : 2009.12.18
  • Accepted : 2010.03.22
  • Published : 2010.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: We performed an immunohistochemical study with pre-treatment biopsy specimens to evaluate the prognostic significance of four biomolecular markers which can be used as a predictive assay for radiotherapy (RT) treatment of nasopharyngeal carcinoma (NPC). Materials and Methods: From January 1998 through December 2006, 68 patients were histologically diagnosed as non-metastatic NPC and treated by RT. Only 38 patients had the paraffin block for the immunohistochemical study. Thirty-one patients had undifferentiated carcinoma and 7 patients had squamous cell carcinoma. Thirtytwo patients (84%) had advanced stage NPC (2002 AJCC Stage III~IV). Immunohistochemical staining was performed for Met, COX-2, nm23-H1, and epidermal growth factor receptor (EGFR) expression using routine methods. Results: The median follow-up time was 30 months (range, 11 to 83 months) for all patients, and 39 months (range, 19 to 83 months) for surviving patients. The 5-year overall survival (OS) rate of the patients with high Met extent (${\geq}50%$) was significantly lower than that of the patients with low Met extent (48% vs. 84%, p=0.02). In addition, Met extent was also a significant prognostic factor in multivariate analysis (p=0.01). No correlation was observed between Met extent and T stage, N stage, stage group, gender, age, and the response to chemotherapy or RT. Met extent showed moderate correlation with COX-2 expression (Pearson coefficient 0.496, p<0.01), but COX-2 expression did not affect OS. Neither nm23-H1 or EGFR expression was a prognostic factor for OS in this study. Conclusion: High Met extent (${\geq}50%$) might be an independent prognostic factor that predicts poor OS in NPC treated with RT.

목 적: 방사선 치료를 받은 코인두암 환자의 치료 전 조직을 면역조직화학염색하여 생체분자적 예후인자를 찾고자 하였다. 대상 및 방법: 1998년부터 2006년까지 방사선 치료를 받은 코인두암환자는 68명이었다. 이중 38명의 환자에서 면역조직화학염색을 위한 파라핀 블록을 찾을 수 있었다. 전체 환자 중 31명은 미분화암종이었고, 7명은 편평세포암종이었다. 전체 환자의 84%가 2002 American Joint Committee on Cancer Stage III or IV 환자였다. 전체 환자의 파라핀 블록을 이용하여 Met, COX-2, epidermal growth factor receptor (EGFR), nm23-H1에 대해 면역조직화학염색을 시행하였다. 결 과: 전체 환자의 중앙 추적 기간은 30개월이었고 생존 환자의 중앙 추적 기간은 39개월이었다. 높은(${\geq}50%$) Met 발현을 보인 환자들의 5년 생존율은 48%, 낮은 Met 발현을 보인 환자들의 5년 생존율은 84%로 이는 통계적으로 유의한 차이를 보였다(p=0.02). Met 발현 정도는 다변량 분석에서도 유의한 인자로 분석되었다(p=0.01). Met 발현은 종양의 병기, 성별, 나이, 항암제나 방사선 치료에 대한 반응 정도와 상관관계를 보이지 않았다. Met 발현 정도는 COX-2 발현과 중등도의 상관관계를 보였으나(Pearson coefficient 0.496, p<0.01), COX-2 발현은 전체생존율에 영향을 미치지 않았다. 본 연구에서는 nm23-H1이나 EGFR의 발현은 예후인자가 아닌 것으로 분석되었다. 결 론: 방사선치료를 받은 코인두암에서, 높은(${\geq}\;50%$) Met 발현은 전체생존율에 영향을 미치는 독립적인 예후인자일 가능성이 있다.

Keywords

References

  1. Ministry for Heath, Welfare and Family Affairs. Annual Report of Cancer Incidence (2005) and Survival (1993-2005) in Korea. Seoul: Ministry for Heath, Welfare and Family Affairs, 2008
  2. Fandi A, Altun M, Azli N, Armand JP, Cvitkovic E. Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol 1994;21:382-397
  3. Kim S, Grandis JR, Rinaldo A, Takes RP, Ferlito A. Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer. Head Neck 2008;30: 667-674 https://doi.org/10.1002/hed.20859
  4. Heng DM, Wee J, Fong KW, et al. Prognostic factors in 677 patients in Singapore with nondisseminated nasopharyngeal carcinoma. Cancer 1999;86:1912-1920 https://doi.org/10.1002/(SICI)1097-0142(19991115)86:10<1912::AID-CNCR6>3.0.CO;2-S
  5. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310-1317
  6. Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005;23:6730-6738 https://doi.org/10.1200/JCO.2005.16.790
  7. Baujat B, Audry H, Bourhis J, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 2006;64:47-56 https://doi.org/10.1016/j.ijrobp.2005.06.037
  8. Qian CN, Guo X, Cao B, et al. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res 2002;62:589-596
  9. Benvenuti S, Comoglio PM. The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 2007;213: 316-325 https://doi.org/10.1002/jcp.21183
  10. Chen WC, McBride WH, Chen SM, et al. Prediction of poor survival by cyclooxygenase-2 in patients with T4 nasopharyngeal cancer treated by radiation therapy: clinical and in vitro studies. Head Neck 2005;27:503-512 https://doi.org/10.1002/hed.20178
  11. Kim K, Wu HG, Park SW, Kim CJ, Park CI. Expression of cyclooxygenase (COX)-2 as a prognostic factor in Nasopharyngeal Cancer. Cancer Res Treat 2004;36:187-191 https://doi.org/10.4143/crt.2004.36.3.187
  12. Guo X, Min HQ, Zeng MS, et al. nm23-H1 expression in nasopharyngeal carcinoma: correlation with clinical outcome. Int J Cancer 1998;79:596-600 https://doi.org/10.1002/(SICI)1097-0215(19981218)79:6<596::AID-IJC7>3.0.CO;2-Y
  13. Ma BB, Poon TC, To KF, et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma: a prospective study. Head Neck 2003;25:864-872 https://doi.org/10.1002/hed.10307
  14. Chua DT, Nicholls JM, Sham JS, Au GK. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2004;59:11-20 https://doi.org/10.1016/j.ijrobp.2003.10.038
  15. Taheri-Kadkhoda Z, Magnusson B, Svensson M, Mercke C, Bjork-Eriksson T. Expression modes and clinical manifestations of latent membrane protein 1, Ki-67, cyclin-B1, and epidermal growth factor receptor in nonendemic nasopharyngeal carcinoma. Head Neck 2009;31:482-492 https://doi.org/10.1002/hed.21002
  16. Leong JL, Loh KS, Putti TC, Goh BC, Tan LK. Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx. Laryngoscope 2004;114:153-157 https://doi.org/10.1097/00005537-200401000-00029
  17. Chae SM, Lee YS, Kim YS, et al. EGFR, p53, Cox-2 and Bcl-2 expression in nasopharyngeal carcinoma and their potential clinical implication. J Korean Soc Ther Radiol Oncol 2007;25:43-53